GlassScriptPhysician profile
Marissa Taylor
NPI 1295431492
$2,645.40
in general payments reported to CMS, 2019-2025
19 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,081 · 2024: $437 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $661.74 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $372.85 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $259.89 | 2023 | Austedo Xr, Austedo, Uzedy |
| Lundbeck LLC | $214.81 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $162.24 | 2023 | Azstarys, Adlarity |
| Abbvie INC. | $139.72 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $136.00 | 2023-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Idorsia Pharmaceuticals US INC | $130.01 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $121.83 | 2023 | Sunosi |
| Bausch Health US, LLC | $107.14 | 2023 | Aplenzin, Wellbutrin |
| Indivior INC. | $92.17 | 2023-2024 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.53 | 2023 | |
| Neurocrine Biosciences, INC. | $60.93 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $36.71 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $23.83 | 2023 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $16.29 | 2023 | Relexxii |
| Neos Therapeutics, LP | $15.80 | 2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $14.60 | 2023 | Trintellix |
| Almatica Pharma LLC | $13.31 | 2023 | Sertraline Hcl, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.